In recent years, life sciences organizations have been looking for a standardized approach to collecting global patient data while maintaining compliance and adhering to study timeline milestones. For clinical trials launched across multiple regions, time zones, and patient populations, the digital revolution toward decentralized clinical trials has caused a colossal shift from collecting patient data via paper patient-reported outcomes (PROs) to an electronic format. Now, more than ever, sponsors aim to empower the global patient voice through patient-centric technologies—including providing wearable technologies and using electronic clinical outcome assessments (eCOAs) to collect patient data.
One of the largest challenges companies running clinical trials face is the complexity of developing an eCOA strategy for digital patient data collection. From navigating the complex world of authors/copyright holders of the instruments to validating multilingual instruments for ensuring data integrity, managing multiple parties in the room, and selecting an eCOA solutions provider that is up to industry standard for localization deployment, all of these factors (and more) directly feed into the complexity that is eCOA data collection. Changes in the COA/eCOA landscape have illustrated the need for centralizing global content solutions for eCOA migration to streamline and simplify patient data reporting, regardless of where a clinical trial is being conducted.
Whether you’re a sponsor or CRO, there are three main benefits to centralizing global content for eCOA migration:
While there’s no specific global regulation that outlines requirements on eCOA migration, organizations such as the FDA, ISPOR, EMA, and others have all released best practices and guidelines to ensure patient data is validated, accurate, and high quality, regardless of the language it is recorded in. By centralizing content, sponsors and CROs are better positioned to address any errors in the initial paper instrument before electronic migration and before adapting to other languages.
Besides following regulatory authorities’ best practices and guidelines, it’s also imperative to get approval from the COA copyright holder (if applicable). Since clinical outcome assessments are intellectual property, any changes (including electronic adaptation and translation) must be approved by the license holder to ensure compliance.
Centralizing eCOA migration activities has benefits beyond reducing time to market and mitigating risk.
If you’d like to learn more about TransPerfect’s eCOA migration technology platform, which can deliver up to 50% shorter eCOA/ePRO migration timelines, reduce migration errors by 97%, and save 25-50% on rush charges, contact us today!